← Back to patent-cliff list
头孢他啶/他唑巴坦钠
Tier C — Watch / tradeCeftazidime/Tazobactam Sodium
湘北威尔曼制药股份有限公司
Originator
2010
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PBPs、Beta Lactamase
Indications (approved)：细菌感染
Regional status
US
-
EU
-
China
批准上市
2010-03-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ceftazidime/Tazobactam Sodium?
Approved indications include: 细菌感染.
When does the Ceftazidime/Tazobactam Sodium patent expire?
No public expiry year is available for Ceftazidime/Tazobactam Sodium yet; this page updates once verified.
How do I get a quote for Ceftazidime/Tazobactam Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24